Chimeric Antigen Receptor T-Cell Therapies for Cancer

Introduction 1. When to Refer a Patient for CAR-T Cell Therapy 2. Optimizing the Apheresis Product 3. CAR T Cells: Cell Processing Laboratory Considerations 4. Peri-CAR-T Cell Management 5. Management of Cytokine Release Syndrome 6. Special Considerations for ICU Management of Patients Receiving CAR Therapy 7. Neurotoxicities After CAR-T Cell Immunotherapy 8. Hematologic and Non-CRS Toxicities 9. Response Assessment and PosteCAR-T Cell Therapy Management 10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy 11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas 12. CAR T Cell Therapy for CNS Malignancies 13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer